Business
Dyadic and The Israel Institute for Biological Research (IIBR) Expand Collaboration to Combat Emerging Diseases
NES-ZIONA, ISRAEL and JUPITER, FL / ACCESSWIRE / February 25, 2020 / Dyadic International, Inc. (''Dyadic'') (NASDAQ:DYAI), a global biotechnology company
About this update from Dyadic International, Inc.
[{"type":"text","content":"NES-ZIONA, ISRAEL and JUPITER, FL / ACCESSWIRE / February 25, 2020 / Dyadic International, Inc. (''Dyadic'') (NASDAQ:DYAI), a global biotechnology company announced today that they are joining the global fight against the coronavirus outbreak by collaborating with The Israel Institute for Biological Research (\"IIBR\"), a governmental research institute established to provide the State of Israel with scientific response to chemical and biological threats.IIBR will explore the potential of Dyadic's industrially proven C1 gene expression platform to express gene sequences and targets developed by IIBR into both an rVaccine candidate and monoclonal antibodies (mAbs) that may help combat the outbreak of the COVID-19 virus (Coronavirus).The research collaboration combines IIBR's renowned scientific capabilities and cGMP facilities with Dyadic's patented and proprietary C1 gene expression platform known to shorten the development cycle, lower the manufacturing cost and improve the performance of vaccines and mAbs.\"Our collaboration with the IIBR is aimed at finding additional solutions to combat the COVID-19 coronavirus outbreak that threathens the lives of people in China and globally,\" commented Mark A. Emalfarb, Founder and CEO of Dyadic. \"There is a global need to apply new platforms and technologies that will facilitate a fast, coordinated and practical response to new infectious diseases during pandemic and epidemic outbreaks or a bioterrorist attack and we believe that Dyadic's C1 technology is well-positioned to contribute to this global effort.\"\"Certain data and results generated from this collaboration are expected to futher validate the versatility and safety of our C1 gene expression platform,\" said Dr. Ronen Tchelet, Dyadic's Chief Scientific Officer.\"The Israel Institute for Biologcal Research was assigned by the Israeli Prime minister, Mr. Benjamin Netanyahu, to act as quickly as possible to produce a vaccine and neutralizing antibodies for the Novel Coronavirus COVID-19,\" said Prof. Shmuel C. Shapira, Director General of IIBR. Prof Shapira continued, \"More than 50 experienced Ph.D. IIBR's scientists are working tirelessly to produce a vaccine and neutralizing antibodies for the Novel Coronavirus COVID-19. This is a world-leading group in aspect of knowledge, experience and infrastructure. The Israel Institute ...